Transport and metabolism of tyrosine kinase inhibitors associated with chronic myeloid leukemia therapy: a review
出版年份 2022 全文链接
标题
Transport and metabolism of tyrosine kinase inhibitors associated with chronic myeloid leukemia therapy: a review
作者
关键词
-
出版物
MOLECULAR AND CELLULAR BIOCHEMISTRY
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2022-02-07
DOI
10.1007/s11010-022-04376-6
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice
- (2021) Valentín Garcia-Gutiérrez et al. Blood Cancer Journal
- A Phase 3, Open-Label, Randomized Study of Asciminib, a STAMP Inhibitor, vs Bosutinib in CML After ≥2 Prior TKIs
- (2021) Delphine Rea et al. BLOOD
- Asciminib: an investigational agent for the treatment of chronic myeloid leukemia
- (2021) Massimo Breccia et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Response and Resistance to BCR-ABL1-Targeted Therapies
- (2020) Theodore P. Braun et al. CANCER CELL
- Nephrotoxicity Associated with Novel Anticancer Agents (Aflibercept, Dasatinib, Nivolumab): Case Series and Nephrological Considerations
- (2020) Luca Piscitani et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The role of bosutinib in the treatment of chronic myeloid leukemia
- (2019) Carlo Gambacorti-Passerini et al. Future Oncology
- Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
- (2019) Timothy P. Hughes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dasatinib dose management for the treatment of chronic myeloid leukemia
- (2018) Moshe Talpaz et al. CANCER
- Pharmacokinetic Assessment of Cooperative Efflux of the Multitargeted Kinase Inhibitor Ponatinib Across the Blood-Brain Barrier
- (2018) Janice K. Laramy et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- ABCC6 plays a significant role in the transport of nilotinib and dasatinib, and contributes to TKI resistance in vitro, in both cell lines and primary patient mononuclear cells
- (2018) Laura N. Eadie et al. PLoS One
- The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression in vitro
- (2018) Laura N. Eadie et al. Oncotarget
- Targeting invadopodia-mediated breast cancer metastasis by using ABL kinase inhibitors
- (2018) Tomer Meirson et al. Oncotarget
- Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1
- (2018) Joseph Schoepfer et al. JOURNAL OF MEDICINAL CHEMISTRY
- Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review
- (2018) Jorge E. Cortes et al. Journal of Hematology & Oncology
- Dasatinib: A Review in Pediatric Chronic Myeloid Leukemia
- (2018) Emma H. McCafferty et al. PEDIATRIC DRUGS
- Novel Pathways of Ponatinib Disposition Catalyzed By CYP1A1 Involving Generation of Potentially Toxic Metabolites
- (2017) De Lin et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1
- (2017) Andrew A. Wylie et al. NATURE
- Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib
- (2016) Jorge E. Cortes et al. AMERICAN JOURNAL OF HEMATOLOGY
- Clinical Pharmacokinetics and Pharmacodynamics of Bosutinib
- (2016) Richat Abbas et al. CLINICAL PHARMACOKINETICS
- Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial
- (2016) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Detection and characterization of ponatinib reactive metabolites by liquid chromatography tandem mass spectrometry and elucidation of bioactivation pathways
- (2016) Adnan A. Kadi et al. RSC Advances
- In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib
- (2015) Sara Redaelli et al. Journal of Hematology & Oncology
- Ponatinib is not transported by ABCB1, ABCG2 or OCT-1 in CML cells
- (2015) L Lu et al. LEUKEMIA
- Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1
- (2015) M S Zabriskie et al. LEUKEMIA
- Ponatinib: Accelerated Disapproval
- (2015) J. F. Gainor et al. ONCOLOGIST
- Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia
- (2014) Carlo Gambacorti-Passerini et al. AMERICAN JOURNAL OF HEMATOLOGY
- Evaluation of pharmacokinetics and safety of ponatinib in subjects with chronic hepatic impairment and matched healthy subjects
- (2014) Narayana I. Narasimhan et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Population Pharmacokinetic and Pharmacodynamic Analysis of Bosutinib
- (2014) Poe-Hirr Hsyu et al. Drug Metabolism and Pharmacokinetics
- Ponatinib enhances anticancer drug sensitivity in MRP7-overexpressing cells
- (2014) YUE-LI SUN et al. ONCOLOGY REPORTS
- Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models
- (2013) Joseph M. Gozgit et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Contribution of Abcc4-Mediated Gastric Transport to the Absorption and Efficacy of Dasatinib
- (2013) B. D. Furmanski et al. CLINICAL CANCER RESEARCH
- A Clinical Study to Examine the Potential Effect of Lansoprazole on the Pharmacokinetics of Bosutinib when Administered Concomitantly to Healthy Subjects
- (2013) Richat Abbas et al. CLINICAL DRUG INVESTIGATION
- A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias
- (2013) J.E. Cortes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Profile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemia
- (2013) Steffen Koschmieder et al. OncoTargets and Therapy
- Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure
- (2012) H. J. Khoury et al. BLOOD
- Overcoming Bcr-Abl T315I mutation by combination of GNF-2 and ATP competitors in an Abl-independent mechanism
- (2012) Mamduh Khateb et al. BMC CANCER
- Modulation of the ATPase and Transport Activities of Broad-Acting Multidrug Resistance Factor ABCC10 (MRP7)
- (2012) E. V. Malofeeva et al. CANCER RESEARCH
- Degree of kinase inhibition achievedin vitroby imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2
- (2012) Laura N. Eadie et al. LEUKEMIA & LYMPHOMA
- The Novel BCR-ABL and FLT3 Inhibitor Ponatinib Is a Potent Inhibitor of the MDR-Associated ATP-Binding Cassette Transporter ABCG2
- (2012) R. Sen et al. MOLECULAR CANCER THERAPEUTICS
- Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias
- (2012) Jorge E. Cortes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Quantitative- and Phospho-Proteomic Analysis of the Yeast Response to the Tyrosine Kinase Inhibitor Imatinib to Pharmacoproteomics-Guided Drug Line Extension
- (2012) Sandra C. dos Santos et al. OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY
- Oxidative stress is involved in Dasatinib-induced apoptosis in rat primary hepatocytes
- (2012) Tao Xue et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib
- (2011) J. E. Cortes et al. BLOOD
- Contribution of Abcc10 (Mrp7) to In Vivo Paclitaxel Resistance as Assessed in Abcc10-/- Mice
- (2011) E. A. Hopper-Borge et al. CANCER RESEARCH
- Dasatinib
- (2011) Paul L. McCormack et al. DRUGS
- Effect of imatinib on the biochemical parameters of the reproductive function in male Swiss albino mice
- (2011) KL Bairy et al. INDIAN JOURNAL OF PHARMACOLOGY
- Crystal Structures of ABL-Related Gene (ABL2) in Complex with Imatinib, Tozasertib (VX-680), and a Type I Inhibitor of the Triazole Carbothioamide Class
- (2011) Eidarus Salah et al. JOURNAL OF MEDICINAL CHEMISTRY
- Dasatinib
- (2010) Fabrizio Condorelli et al. BIODRUGS
- BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib
- (2010) D. W. Sherbenou et al. BLOOD
- Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes
- (2010) Noelia Nebot et al. BRITISH JOURNAL OF PHARMACOLOGY
- Structural Mechanism of the Pan-BCR-ABL Inhibitor Ponatinib (AP24534): Lessons for Overcoming Kinase Inhibitor Resistance
- (2010) Tianjun Zhou et al. Chemical Biology & Drug Design
- Drug Transporters and Imatinib Treatment: Implications for Clinical Practice
- (2010) K. Eechoute et al. CLINICAL CANCER RESEARCH
- Effects of hepatic impairment on the pharmacokinetics of nilotinib: An open-label, single-dose, parallel-group study
- (2010) Ophelia Q.P. Yin et al. CLINICAL THERAPEUTICS
- Metabolism considerations for kinase inhibitors in cancer treatment
- (2010) Derek R Duckett et al. Expert Opinion on Drug Metabolism & Toxicology
- Effect of Ketoconazole on the Pharmacokinetics of Oral Bosutinib in Healthy Subjects
- (2010) Richat Abbas et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy
- (2010) J Rafael Sierra et al. Molecular Cancer
- Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
- (2010) Giuseppe Saglio et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dasatinib
- (2009) Susan J Keam BIODRUGS
- Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties
- (2009) C Hegedűs et al. BRITISH JOURNAL OF PHARMACOLOGY
- AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
- (2009) Thomas O'Hare et al. CANCER CELL
- Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects
- (2009) Jorg Hartmann et al. CURRENT DRUG METABOLISM
- Impact of BaselineBCR-ABLMutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase
- (2009) Timothy Hughes et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of the Effect of Gastric Acid pH Modulators on the Bioavailability of Oral Dasatinib in Healthy Subjects
- (2009) Timothy Eley et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Imatinib mesylate-induced acute liver failure in a patient with gastrointestinal stromal tumors
- (2009) Onder Tonyali et al. MEDICAL ONCOLOGY
- Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I
- (2008) A. Gontarewicz et al. BLOOD
- Interaction of Imatinib with Human Organic Ion Carriers
- (2008) S. Hu et al. CLINICAL CANCER RESEARCH
- Dasatinib Cellular Uptake and Efflux in Chronic Myeloid Leukemia Cells: Therapeutic Implications
- (2008) D. K. Hiwase et al. CLINICAL CANCER RESEARCH
- Tasigna for Chronic and Accelerated Phase Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia Resistant to or Intolerant of Imatinib
- (2008) M. Hazarika et al. CLINICAL CANCER RESEARCH
- Metabolism and Disposition of Dasatinib after Oral Administration to Humans
- (2008) L. J. Christopher et al. DRUG METABOLISM AND DISPOSITION
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started